REG - Nuformix PLC - Subscription to raise £150,000

NuformixAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA0557Fa&default-theme=true

RNS Number : 0557F  Nuformix PLC  01 March 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK
LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN
ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN
THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH
INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS
SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

1 March 2024

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Subscription to raise £150,000

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces a
subscription to raise gross proceeds of £150,000 through a subscription for
75,000,000 new ordinary shares of 0.1 pence in the capital of the Company (the
"New Ordinary Shares") at a price of 0.20 pence per share (the
"Subscription").  The New Ordinary Shares will represent approximately 9.2
per cent. of the Company's enlarged issued share capital and are being issued
pursuant to the Company's existing share issuance authorities.

 

The net proceeds of the Subscription will be used by the Company primarily to
further advance its NXP002 programme for the inhaled treatment of idiopathic
pulmonary fibrosis ("IPF").

 

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "The funds
raised through the Subscription will support the Company as we focus on
discussions with potential licensees and the overall progression of the NXP002
programme to improve the treatment of IPF via inhalation.  I look forward to
providing further updates in due course."

 

Admission and Total Voting Rights

 

Application will be made for the 75,000,000 New Ordinary Shares to be admitted
to the Official List of the FCA and to trading on the Main Market of the
London Stock Exchange ("Admission"). It is expected that Admission will become
effective and that unconditional dealings will commence on the London Stock
Exchange at 8.00 a.m. on 6 March 2024.

 

Following Admission of the New Ordinary Shares, the total number of Ordinary
Shares in issue will be 819,309.368, each with one voting right.  The Company
does not hold any rights in treasury.  The total voting rights figure is
therefore 819,309,368 and can be used by shareholders as the denominator for
the calculations by which they will determine whether they are required to
notify their interest in, or a change of their interest in, the Company under
the Disclosure Guidance and Transparency Rules of the Financial Conduct
Authority.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 Bob Pountney (Corporate Broking)                  +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEQKCBPOBKDPBB